Evaluation of labelingparameters of PSMA-617 with 213Bi for targeted alpha-radionuclide therapy of metastatic castration-resistant prostate cancer

被引：0
|
作者：
Khoshhosn, H. [1 ]
Davarpanah, M. [1 ]
Khoshhosn, H. [1 ]
Gravand, A. [1 ]
Tavakoli, Y. [1 ]
Soltani, N. [1 ]
Harati, M. [1 ]
Kalantari, B. [1 ]
Johri, F. [1 ]
机构：
[1] Pars Isotope Co, Tehran, Iran
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-720
引用
收藏
页码：S326 / S326
页数：1
相关论文
共 50 条
  • [21] PSMA-Targeted Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
    Sartor, A. Oliver
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 494 - 496
  • [22] Novel 212Pb-PSMA Targeted Alpha Therapy for the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Kryza, T.
    Liu, F.
    Li, K. C.
    Francis, P.
    Kuan, K.
    Tieu, W.
    Akhter, D.
    Fletcher, N.
    Taylor, S.
    Karmann, A.
    Rose, S.
    Puttick, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S254 - S255
  • [23] Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
    Gadot, Moran
    Davidson, Tima
    Aharon, Margalit
    Atenafu, Eshetu G.
    Malki, Avraham
    Levartovsky, Meital
    Saad, Akram
    Domachevsky, Liran
    Berger, Raanan
    Leibowitz, Raya
    CANCERS, 2020, 12 (05)
  • [24] PSMA radioligand therapy (PRLT) of metastatic castration-resistant prostate cancer: first results using the PSMA Inhibitor 617
    Kulkarni, Harshad
    Singh, Aviral
    Niepsch, Karin
    Schuchardt, Christiane
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [25] 225Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
    Ballal, Sanjana
    Yadav, Madhav P.
    Sahoo, Ranjit K.
    Tripathi, Madhavi
    Dwivedi, Sada N.
    Bal, Chandrasekhar
    PROSTATE, 2021, 81 (09): : 580 - 591
  • [26] Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Hadaschik, Boris
    Herrmann, Ken
    EUROPEAN UROLOGY, 2021, 80 (04) : 520 - 521
  • [27] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [28] Actinium-225 PSMA-617 therapy in metastatic castration resistant prostate cancer - Single center retrospective study
    Gunasekaran, V.
    Kumar, S.
    Sood, A.
    Aggarwal, P.
    Mittal, B. R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S420 - S421
  • [29] Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Sartor, O.
    de Bono, J.
    Chi, K. N.
    Fizazi, K.
    Herrmann, K.
    Rahbar, K.
    Tagawa, S. T.
    Nordquist, L. T.
    Vaishampayan, N.
    El-Haddad, G.
    Park, C. H.
    Beer, T. M.
    Armour, A.
    Perez-Contreras, W. J.
    DeSilvio, M.
    Kpamegan, E.
    Gericke, G.
    Messmann, R. A.
    Morris, M. J.
    Krause, B. J.
    JOURNAL OF UROLOGY, 2022, 207 (02): : 467 - 468
  • [30] Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
    Kinikoglu, Oguzcan
    Oven, Bala Basak
    Celik, Serkan
    Selcuk, Nalan Alan
    Beydagi, Gamze
    Akcay, Kaan
    Kabasakal, Levent
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
12345